Cargando…

Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men

CONTEXT: Glucose and lipids stimulate the gut-hormones glucagon-like peptide (GLP)-1, GLP-2 and glucose-dependent insulinotropic polypeptide (GIP) but the effect of these on human postprandial lipid metabolism is not fully clarified. OBJECTIVE: To explore the responses of GLP-1, GLP-2 and GIP after...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matikainen, Niina, Björnson, Elias, Söderlund, Sanni, Borén, Christofer, Eliasson, Björn, Pietiläinen, Kirsi H., Bogl, Leonie H., Hakkarainen, Antti, Lundbom, Nina, Rivellese, Angela, Riccardi, Gabriele, Després, Jean-Pierre, Alméras, Natalie, Holst, Jens Juul, Deacon, Carolyn F., Borén, Jan, Taskinen, Marja-Riitta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709062/ https://www.ncbi.nlm.nih.gov/pubmed/26752550 http://dx.doi.org/10.1371/journal.pone.0145890

Ejemplares similares

Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single‐centre randomized controlled study
por: Matikainen, Niina, et al.
Publicado: (2018)

Contribution of intestinal triglyceride-rich lipoproteins to residual atherosclerotic cardiovascular disease risk in individuals with type 2 diabetes on statin therapy
por: Taskinen, Marja-Riitta, et al.
Publicado: (2023)

Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans
por: Borén, Jan, et al.
Publicado: (2020)

Genetic Variation in SULF2 Is Associated with Postprandial Clearance of Triglyceride-Rich Remnant Particles and Triglyceride Levels in Healthy Subjects
por: Matikainen, Niina, et al.
Publicado: (2013)

GLP-1 and GLP-2 as Yin and Yang of Intestinal Lipoprotein Production: Evidence for Predominance of GLP-2–Stimulated Postprandial Lipemia in Normal and Insulin-Resistant States
por: Hein, Gustavo J., et al.
Publicado: (2013)

Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations
por: Taskinen, Marja-Riitta, et al.
Publicado: (2022)

GLP-1 and Intestinal Diseases
por: Hunt, Jenna Elizabeth, et al.
Publicado: (2021)

Characterization of different fat depots in NAFLD using inflammation-associated proteome, lipidome and metabolome
por: Lovric, Alen, et al.
Publicado: (2018)

N‐terminal alterations turn the gut hormone GLP‐2 into an antagonist with gradual loss of GLP‐2 receptor selectivity towards more GLP‐1 receptor interaction
por: Gabe, Maria Buur Nordskov, et al.
Publicado: (2022)

From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
por: Holst, Jens Juul
Publicado: (2019)

The Sensory Mechanisms of Nutrient-Induced GLP-1 Secretion
por: Hjørne, Anna Pii, et al.
Publicado: (2022)

Personal model‐assisted identification of NAD(+) and glutathione metabolism as intervention target in NAFLD
por: Mardinoglu, Adil, et al.
Publicado: (2017)

What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?
por: Holst, Jens Juul
Publicado: (2021)

Exploring the GLP-1–GLP-1R axis in porcine pancreas and gastrointestinal tract in vivo by ex vivo autoradiography
por: Manell, Elin, et al.
Publicado: (2021)

Factors associated with postprandial lipemia and apolipoprotein A-V levels in individuals with familial combined hyperlipidemia
por: Almeda-Valdes, Paloma, et al.
Publicado: (2014)

Cardiac steatosis and left ventricular function in men with metabolic syndrome
por: Nyman, Kristofer, et al.
Publicado: (2013)

Dietary Impact on Postprandial Lipemia
por: Bozzetto, Lutgarda, et al.
Publicado: (2020)

Specific inhibition of bile acid transport alters plasma lipids and GLP-1
por: Rudling, Mats, et al.
Publicado: (2015)

Investigation of human apoB48 metabolism using a new, integrated non‐steady‐state model of apoB48 and apoB100 kinetics
por: Björnson, E., et al.
Publicado: (2019)

Effect of oral contraceptives and/or metformin on GLP-1 secretion and reactive hypoglycaemia in polycystic ovary syndrome
por: Glintborg, Dorte, et al.
Publicado: (2017)

Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?
por: Taskinen, Marja-Riitta, et al.
Publicado: (2016)

Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study
por: Björnson, Elias, et al.
Publicado: (2023)

GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes
por: Mentis, Nikolaos, et al.
Publicado: (2011)

Removal of Duodenum Elicits GLP-1 Secretion
por: Muscogiuri, Giovanna, et al.
Publicado: (2013)

Purslane Effect on GLP-1 and GLP-1 receptor in type 2 diabetes
por: Heidarzadeh, Sara, et al.
Publicado: (2013)

Novel agonist and antagonist radioligands for the GLP‐2 receptor. Useful tools for studies of basic GLP‐2 receptor pharmacology
por: Gadgaard, Sarina, et al.
Publicado: (2022)

The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice
por: Ørgaard, Anne, et al.
Publicado: (2017)

The effect of DPP-4-protected GLP-1 (7–36) on coronary microvascular function in obese adults
por: Nilsson, Malin, et al.
Publicado: (2019)

Allosteric Modulation of the Activity of the Glucagon-like Peptide-1 (GLP-1) Metabolite GLP-1 9–36 Amide at the GLP-1 Receptor
por: Li, Naichang, et al.
Publicado: (2012)

Brain GLP‐1 and the regulation of food intake: GLP‐1 action in the brain and its implications for GLP‐1 receptor agonists in obesity treatment
por: Trapp, Stefan, et al.
Publicado: (2021)

Effect of HDL composition and particle size on the resistance of HDL to the oxidation
por: Shuhei, Nakanishi, et al.
Publicado: (2010)

Effect of GLP-1/GLP-1R on the Polarization of Macrophages in the Occurrence and Development of Atherosclerosis
por: Yang, Li, et al.
Publicado: (2021)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

Is Endogenous GLP-1 the Only Important Enhancer of Glucose-Induced Insulin Secretion in Type 2 Diabetes?
por: Deacon, Carolyn F.
Publicado: (2012)

GLP‐1 Is a Coronary Artery Vasodilator in Humans
por: Clarke, Sophie J., et al.
Publicado: (2018)

Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
por: Madsen, Mette Simone Aae, et al.
Publicado: (2019)

GLP1 and glucagon co-secreting pancreatic neuroendocrine tumor presenting as hypoglycemia after gastric bypass
por: Guimarães, Marta, et al.
Publicado: (2015)

Influence of GLP-1 on Myocardial Glucose Metabolism in Healthy Men during Normo- or Hypoglycemia
por: Gejl, Michael, et al.
Publicado: (2014)

Glucagon, GLP-1 and Thermogenesis
por: González-García, Ismael, et al.
Publicado: (2019)

Glucolipotoxicity and GLP-1 secretion
por: Hong, Jung-Hee, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l31vqape78un10v0o0ipeipm1e